2025 JSH倒计时启动！“延续与连通”赋能血液学，哪些中国专家站上ORAL讲台？看这里

摘要号

英文标题

报告人及单位

O1-13A-1

Safety and efficacy of bicistronic CD19/CD22 CAR T cell therapy in treatment of childhood R/R B-ALL

Hua Zhang，上药生物治疗（香港）有限公司

O1-15A-5

Hepatitis C virus and prognosis of hematologic malignancies: a propensity score matching analysis

Wan-Shiuan Lin，台湾康宁大学

O1-15A-6

Respiratory syncytial virus: a significant cause of respiratory failure in hematologic malignancies

ZongHan Yao，国立台湾大学医学院附设医院

O1-17D-5

The prognostic value of circulating cell-free methylated EBV-DNA in extranodal NK/T cell lymphoma

Tong-Yao Xing，南京医科大学第一附属医院（江苏省人民医院）

O1-17D-6

ABBV-CLS-484 disrupts mitochondrial renewal and mitophagy to exert anti-tumor activities in ALK+ALCL

梁金花，南京医科大学第一附属医院（江苏省人民医院）

O1-18C-2

Glofitamab plus selinexor as salvage therapy for relapsed primary central nervous system lymphoma

Qu Cui，首都医科大学

O1-18C-4

Preliminary exploration of R-MIAD in the treatment of newly diagnosed PCNSL

Yuedan Chen，首都医科大学

O1-19A-3

Exome and transcriptome sequencing reveal prognostic mutation genes in Chinese MM

Ling Zhong，四川省人民医院

O2-3A-3

BRD4 inhibition by MS-417 suppresses TAL1 expression and proliferation in T-ALL cells

赵维莅，上海交通大学医学院附属瑞金医院

O2-3A-4

The anti-leukemic effect of a new CX4945 biomimetic nanodrug in B-cell acute lymphoblastic leukemia

Yan Wang，东南大学附属中大医院

O2-3B-1

Relapse risk and outcome of discontinuing asparaginase in children with acute lymphoblastic leukemia

Xingchen Wang，中国医学科学院血液病医院（中国医学科学院血液学研究所）

O2-3B-3

Synergy efficacy of HDACi and CX-4945 by targeting TCL1A in B-cell acute lymphoblastic leukemia

Huimin Xiang，东南大学附属中大医院

O2-3B-6

Azathioprine in childhood acute lymphoblastic leukemia: a single-center retrospective study

Jianhua Feng，宁波大学附属妇女儿童医院

O2-4C-1

Single-cell analysis reveals myeloid bias and therapeutic targets in pediatric NRAS-mutant neoplasms

Su Y. Zong，中国医学科学院血液病医院（中国医学科学院血液学研究所）

O2-5A-1

Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria

Yuemin Gong，南京医科大学第一附属医院（江苏省人民医院）

O2-5A-4

Iptacopan combined with immunosuppressants for refractory AIHA: a report of three cases

许书倩，山东大学齐鲁医院

O2-9A-3

Long-term remission with CD19/22 CART or in combination with ASCT in TP53-altered B-NHL

Juan Peng，华中科技大学同济医学院附属同济医院

O2-9B-1

Prognostic role of SOCS1 mutations in diffuse large B-cell lymphoma

Xinyi Zhang，南京医科大学第一附属医院（江苏省人民医院）

O2-9B-2

Molecular features encoded in dynamic ctDNA monitoring reveal prognosis and clone evolution in DLBCL

梁金花，南京医科大学第一附属医院（江苏省人民医院）

O2-9B-3

A novel CD58 mutation-related signature predicts prognosis risk in diffuse large B-cell lymphoma

ChunYu Shang，南京医科大学第一附属医院（江苏省人民医院）

O2-9B-4

Identifying the truly low-risk patients with TNFRSF14 mutation in diffuse large B cell lymphoma

Wei Hua，南京医科大学第一附属医院（江苏省人民医院）

O2-11C-6

NSUN2-mediated m5C modification regulates PHGDH and immune evasion in high-grade B-cell lymphoma

Guojun Zhang，中国医科大学附属盛京医院

O2-15D-1

Comparasion of hetrombopag versus eltrombopag combined with ATG/CyA as first-line therapy for SAA

Jingnan Sun，吉林大学第一医院

O2-15D-2

Association of cyclosporin concentration with related adverse events in patients of aplastic anemia

Lingxiao Xing，中国医学科学院血液病医院（中国医学科学院血液学研究所）

O2-15D-3

Management strategy in AA patients with HBV infection following intensive immunosuppressive therapy

Yawen Zhang，南京医科大学第一附属医院（江苏省人民医院）

O2-16C-2

Innovative synergy of flavonoid GL-V9 and EZH2 inhibitor in AML: in vitro and in vivo insights

Chan Yang，东南大学附属中大医院

O2-16D-2

ACTR5 mutation as a prognostic factor in acute myeloid leukemia receiving 3+7 therapy

Jinping He，广州医科大学

O2-17D-3

Sorafenib reverses venetoclax resistance in AML via downregulation of the Ras-Raf-MEK-ERK pathway

Yutong Jin，安徽中医药大学

O2-17D-6

Small-molecule RPB1 degraders eradicate acute myeloid leukemia

Shu wen Zheng，浙江大学医学院附属第二医院

O2-18A-3

Immune landscape profiling in patients with advanced myeloid malignancies receiving azacitidine

Feng-Ming Tien，国立台湾大学医学院附设医院

O2-18C-3

Clinical efficacy and safety of VAH and VAHA regimen in newly diagnosed AML patients

Xin Yan，东南大学附属中大医院

O2-18D-5

The prognostic significance of PWWP2B expression in AML patients treated with intensive chemotherapy

Cheng Yeh Chen，国立台湾大学医学院附设医院

O3-4C-4

Comparative analysis of secondary malignancies in MF patients treated with ruxolitinib

Yu-Guang Chen，台湾三军总医院

O3-4C-5

Clinical features, gene alterations, and outcomes in primary myelofibrosis with ring sideroblasts

Junyun Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所）

O3-8B-1

Clinical implication of residual genetic mutations at CR in acute myeloid leukemia

Xin Yan，东南大学附属中大医院

O3-8B-2

Prognostic implications of BCMA, BAFF, and APRIL expression in patients with acute myeloid leukemia

Yun-Tzu Lin，国立台湾大学医学院附设医院

O3-8B-3

A clinically actionable prognostic model for infant acute myeloid leukemia

Yu Tao，重庆医科大学附属儿童医院

O3-8B-4

Identification of a stress-adapted pDC-like leukemic stem cell program in pDC-AML by multi-omics

Xingcheng Yang，华中科技大学同济医学院附属同济医院

O3-14A-2

Risk factors, and imaging findings of bronchiolitis obliterans syndrome after allogeneic SCT

Ting-Yu Liao，国立台湾大学医学院附设医院

O3-14A-5

Prognostic value of patient telomere length in Allo-HSCT for hematologic malignancies

Hengwei Wu，宁波市鄞州人民医院

O3-14B-2

Machine learning-based prediction of stem cell harvest success: a single institution experience

Heng Lee，台北荣民总医院

O3-17D-2

DNA methylation variability in pediatric aplastic anemia contributes to T cell differentiation

Inan Wang，上海交通大学医学院附属上海儿童医学中心

O3-18A-6

Bortezomib in VRCAP/VRDHAP induction improves outcomes in untreated mantle cell lymphoma

Wan-Chen Hsieh，国立台湾大学医学院附设医院